Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures.

BACKGROUND

B-cell depleting drugs show promise for treating multiple sclerosis.

OBJECTIVE

We sought predictors of optimal response to rituximab, a B-cell depleting antibody, to help guide therapy selection.

METHODS

We performed a post hoc study of 30 relapsing multiple sclerosis patients with breakthrough disease while on beta-interferon or glatiramer acetate who were treated with add-on rituximab. Standardized neurologic examinations, brain magnetic resonance imaging, and cerebrospinal fluid were obtained before and after rituximab. Tissue biomarkers were measured. Optimal responders were defined as having no evidence of disease activity.

RESULTS

At baseline, optimal responders with no evidence of disease activity had higher IgG indices ( = 0.041), and higher CXCL13 indices ((cerebrospinal fluid CXCL13/serum CXCL13)/albumin index;  = 0.024), more contrast enhancing lesions ( = 0.002), better 25 foot timed walk ( = 0.001), and Expanded Disability Status Scale ( = 0.002). Rituximab treatment led to reduced cerebrospinal fluid biomarkers of tissue destruction: myelin basic protein ( = 0.046), neurofilament light chain ( < 0.001), and of inflammation (CXCL13 index;  = 0.042).

CONCLUSIONS

Multiple sclerosis patients with optimal response to rituximab had higher cerebrospinal fluid IgG and CXCL13 indices, more gadolinium-enhancing lesions, and less disability at baseline. Rituximab treatment led to decreased markers of inflammation and tissue damage. If validated, these results will help identify multiple sclerosis patients who will respond optimally to B-cell depletion.